Fundamentals screen · refreshed after the Nov 9, 2026 close
Net-cash companies: Healthcare
Companies whose cash and investments exceed all debt by at least a quarter of their market value. Net cash is cash plus short-term investments minus debt, from the latest quarterly balance sheet.
| # | Company | Price | Net cash | Mkt cap | Revenue YoY | P/E |
|---|---|---|---|---|---|---|
| 51 | MOBIMobia MedicalHealthcare | $12.26 | $153.4M | $408.1M | — | — |
| 52 | MLTXMoonLake ImmunotherapeuticsHealthcare | $12.62 | $398.5M | $1.07B | — | — |
| 53 | EDITEditas MedicineHealthcare | $2.75 | $155.9M | $422.3M | +232.3% | — |
| 54 | IPSCCentury TherapeuticsHealthcare | $1.81 | $119.7M | $327.7M | — | — |
| 55 | DNAGinkgo Bioworks HoldingsHealthcare | $12.37 | $302.2M | $833.0M | −48.5% | — |
| 56 | DMRADamora TherapeuticsHealthcare | $24.07 | $528.5M | $1.49B | — | — |
| 57 | ODTXOdyssey TherapeuticsHealthcare | $19.15 | $326.0M | $920.5M | — | — |
| 58 | FLGTFulgent GeneticsHealthcare | $26.15 | $256.6M | $730.6M | +4.4% | — |
| 59 | OCULOcular TherapeutixHealthcare | $6.85 | $525.8M | $1.50B | +0.1% | — |
| 60 | CRSPCRISPR Therapeutics AGHealthcare | $50.04 | $1.69B | $4.85B | +1325.1% | — |
| 61 | ACADAcadia PharmaceuticalsHealthcare | $16.50 | $976.4M | $2.85B | +22.8% | 7.9× |
| 62 | CBIOCrescent BiopharmaHealthcare | $13.65 | $171.6M | $507.1M | — | — |
| 63 | BEAMBeam TherapeuticsHealthcare | $27.02 | $943.5M | $2.80B | −96.8% | — |
| 64 | AGIOAgios PharmaceuticalsHealthcare | $31.38 | $630.0M | $1.88B | +330.0% | — |
| 65 | CTKBCytek BiosciencesHealthcare | $5.89 | $255.8M | $770.3M | +1.8% | — |
| 66 | EWTXEdgewise TherapeuticsHealthcare | $48.74 | $1.74B | $5.34B | — | 5.3× |
| 67 | IMMXImmix BiopharmaHealthcare | $8.57 | $232.1M | $710.5M | — | — |
| 68 | XFORX4 PharmaceuticalsHealthcare | $3.33 | $110.7M | $340.0M | +63.1% | — |
| 69 | CLYMClimb BioHealthcare | $11.01 | $205.4M | $646.7M | — | — |
| 70 | HRMYHarmony Biosciences HoldingsHealthcare | $33.78 | $622.0M | $1.98B | +12.3% | 11.1× |
| 71 | SGMTSagimet Biosciences Inc. Series AHealthcare | $10.83 | $240.1M | $767.9M | — | — |
| 72 | DSGNDesign TherapeuticsHealthcare | $10.80 | $208.6M | $691.6M | — | — |
| 73 | PBLSParabilis MedicinesHealthcare | $30.37 | $1.11B | $3.75B | — | — |
| 74 | SBCSBC Medical Group Holdings IncorporatedHealthcare | $5.26 | $160.4M | $541.0M | +13.4% | 11.0× |
| 75 | MOVMovado GroupHealthcare | $32.03 | $211.6M | $714.7M | +4.9% | 17.3× |
| 76 | PTCTPTC TherapeuticsHealthcare | $65.03 | $1.59B | $5.43B | +69.6% | — |
| 77 | RZLTRezolute, Inc. Common Stock (NV)Healthcare | $3.87 | $107.8M | $374.3M | — | — |
| 78 | NAUTNautilus BiotechnolgyHealthcare | $2.38 | $86.6M | $303.1M | — | — |
| 79 | TSHATaysha Gene TherapiesHealthcare | $4.37 | $406.1M | $1.42B | −100.0% | — |
| 80 | LBRXLB PharmaceuticalsHealthcare | $45.12 | $403.8M | $1.46B | — | — |
| 81 | ORICOric PharmaceuticalsHealthcare | $9.23 | $264.8M | $956.7M | — | — |
| 82 | NAMSNewAmsterdam Pharma Company N.VHealthcare | $19.00 | $628.2M | $2.28B | +5406.9% | — |
| 83 | MNPRMonopar TherapeuticsHealthcare | $73.75 | $134.3M | $495.0M | — | — |
| 84 | SRZNSurrozenHealthcare | $32.00 | $102.0M | $376.1M | +408.6% | — |
| 85 | IDYAIDEAYA BiosciencesHealthcare | $32.03 | $838.5M | $3.10B | −95.1% | — |
| 86 | CLDXCelldex TherapeuticsHealthcare | $31.24 | $650.3M | $2.45B | — | — |
| 87 | TNGXTango TherapeuticsHealthcare | $22.74 | $1.01B | $3.83B | −100.0% | — |
| 88 | ANNXAnnexonHealthcare | $4.23 | $209.2M | $801.9M | — | — |
| 89 | ZVRAZevra TherapeuticsHealthcare | $12.14 | $188.3M | $722.4M | +44.9% | 9.4× |
| 90 | BBNXBeta BionicsHealthcare | $16.95 | $240.2M | $921.5M | +30.3% | — |
| 91 | DYNDyne TherapeuticsHealthcare | $18.62 | $909.0M | $3.49B | — | — |
| 92 | AVLNAvalyn PharmaHealthcare | $29.50 | $337.6M | $1.31B | — | — |
| 93 | NTLAIntellia TherapeuticsHealthcare | $12.11 | $437.8M | $1.70B | −46.2% | — |
| 94 | RAPPRapport TherapeuticsHealthcare | $26.07 | $395.0M | $1.55B | — | — |
Method & sources
Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology
Informational screen, not a recommendation.